Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exact Sciences Cor (EXAS)

Exact Sciences Cor (EXAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,183,938
  • Shares Outstanding, K 189,471
  • Annual Sales, $ 2,759 M
  • Annual Income, $ -1,029 M
  • EBIT $ -220 M
  • EBITDA $ 864 M
  • 60-Month Beta 1.42
  • Price/Sales 6.95
  • Price/Cash Flow 17.97
  • Price/Book 7.66

Options Overview Details

View History
  • Implied Volatility 6.89% (-0.81%)
  • Historical Volatility 76.32%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 76.81% on 08/01/25
  • IV Low 6.89% on 12/04/25
  • Expected Move (DTE 15) 1.35 (1.34%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 965
  • Volume Avg (30-Day) 4,240
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 59,980
  • Open Int (30-Day) 48,419
  • Expected Range 99.78 to 102.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.00
  • Number of Estimates 4
  • High Estimate 0.20
  • Low Estimate -0.23
  • Prior Year -0.06
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.92 +55.78%
on 11/07/25
101.87 -0.73%
on 11/20/25
+31.54 (+45.32%)
since 11/04/25
3-Month
51.18 +97.60%
on 09/05/25
101.87 -0.73%
on 11/20/25
+49.72 (+96.71%)
since 09/04/25
52-Week
38.81 +160.57%
on 08/07/25
101.87 -0.73%
on 11/20/25
+36.99 (+57.67%)
since 12/04/24

Most Recent Stories

More News
3 Overrated Stocks That Concern Us

3 Overrated Stocks That Concern Us

MOV : 20.94 (-1.27%)
EXAS : 101.13 (-0.12%)
NEO : 12.17 (+0.41%)
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

SEMR : 11.84 (unch)
MRSN : 27.47 (-1.36%)
EXAS : 101.13 (-0.12%)
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSN

NEW YORK , Nov. 27, 2025 / PRNewswire/ --

SEE : 42.28 (-0.45%)
MRSN : 27.47 (-1.36%)
EXAS : 101.13 (-0.12%)
CDTX : 220.50 (-0.22%)
Halper Sadeh LLC Encourages GDOT, BLFY, EXAS Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

BLFY : 11.97 (+1.18%)
GDOT : 13.21 (+0.15%)
EXAS : 101.13 (-0.12%)
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium

First clinical validation of the Oncodetect ® test to be presented in triple negative breast cancer; signals highly sensitive molecular residual disease (MRD) detection ...

EXAS : 101.13 (-0.12%)
Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks

Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks

EXAS : 101.13 (-0.12%)
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Exact Sciences ...

ABT : 125.40 (+0.09%)
EXAS : 101.13 (-0.12%)
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director

IDYA : 36.01 (+4.86%)
TROW : 105.79 (+0.70%)
EXAS : 101.13 (-0.12%)
ILMN : 128.03 (+0.06%)
TMO : 575.24 (-0.90%)
SERA : 2.98 (-3.56%)
IR : 79.99 (+0.30%)
MTD : 1,422.81 (-0.84%)
QTRX : 7.70 (+2.94%)
LIFE : 1.9000 (+2.70%)
Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?

Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

ABT : 125.40 (+0.09%)
EXAS : 101.13 (-0.12%)
PFE : 25.70 (+0.51%)
Shareholder Alert: The Ademi Firm investigates whether Exact Sciences Corporation is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Nov. 20, 2025 /PRNewswire/ -- The Ademi Firm is investigating Exact Sciences (NASDAQ: EXAS) for possible breaches of fiduciary duty and other violations of law in its recently announced...

EXAS : 101.13 (-0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and...

See More

Key Turning Points

3rd Resistance Point 101.72
2nd Resistance Point 101.54
1st Resistance Point 101.34
Last Price 101.13
1st Support Level 100.95
2nd Support Level 100.77
3rd Support Level 100.57

See More

52-Week High 101.87
Last Price 101.13
Fibonacci 61.8% 77.78
Fibonacci 50% 70.34
Fibonacci 38.2% 62.90
52-Week Low 38.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar